Hyperprogressive disease (HPD) is a new pattern of progression recently described in patients with cancer treated with programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors. The rate and outcome of HPD in advanced non-small cell lung cancer (NSCLC) are unknown.
I n the era of immuno-oncology, programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have demonstrated a clear survival benefit as a single agent or in combination compared with standard chemotherapy in both treatment-naive patients [1] [2] [3] [4] and patients previously treated 5-8 for advanced non-small cell lung cancer (NSCLC). However, progression rates reported with single-agent PD-1/PD-L1 inhibitors are in some cases equal to or higher than with conventional treatment, ranging from 33% to 44% in pretreated patients with NSCLC. [5] [6] [7] Recently, an acceleration of tumor growth during immunotherapy, defined as hyperprogressive disease (HPD), was reported in 9% of advanced cancers 9 and in 29% of patients with head and neck cancer 10 treated with PD-1/ PD-L1 inhibitors. The tumor growth rate (TGR) is a tool for estimating the increase in tumor volume over time based on 2 computed tomography (CT) scan measurements. 11 The TGR takes into account the sum of the target lesions defined by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) and the interval between 2 CT scans. It can be used to quantitatively assess tumor dynamics and kinetics during treatment; specifically, it can be applied to identify the subset of patients experiencing HPD.
To explore if HPD is an unforeseen pattern of progression during IO therapy in NSCLC, we compared the TGR before and during IO therapy in a cohort of pretreated patients with advanced NSCLC. To investigate if HPD is a specific PD-1/PD-L1 inhibitor pattern, we assessed the TGR and HPD prevalence among a control cohort receiving single-agent chemotherapy.
Methods

Patients and Treatment
In this multicenter study, data were retrospectively collected from all consecutive eligible patients with advanced NSCLC treated with IO (nivolumab, pembrolizumab, atezolizumab, or durvalumab) from November 10, 2012, to April 5, 2017, in 8 French institutions. For the control cohort, equivalent data were collected in patients with advanced NSCLC failing a platinum-based regimen and treated with single-agent chemotherapy (taxanes, pemetrexed, vinorelbine tartrate, or gemcitabine chlorohydrate) from August 4, 2011, to June 13, 2016 , in 4 French institutions.
To be eligible, patients had to be 18 years or older, with histologically or cytologically confirmed stage III or IV NSCLC and available CT scans for radiological evaluation. In the singleagent chemotherapy control cohort, patients who received previous treatment with IO were excluded. The PD-L1 expression was analyzed by immunohistochemistry on tumor cells in archived biopsy specimens, when available, and the cutoff for positivity was 1%. This study was approved by the institutional review board of Gustave Roussy, and informed consent from participants was not required because of the retrospective nature.
Radiological Evaluation
At least 2 CT scans before PD-1/PD-L1 inhibitor therapy or chemotherapy (baseline and the most recent scan before baseline) and 1 CT scan during treatment were mandatory for radiological evaluation. The baseline CT had to be performed within 6 weeks before initiating treatment, and a minimum of 2 weeks between CT scans was required. All CT scans were centrally reviewed by 2 senior radiologists (L.T. and C.C.). The target lesions were defined according to RECIST version 1.1. An extensive assessment of noneligibility for radiological evaluation was performed in 1 center (Gustave Roussy) to refine inclusion of patients in subsequent centers. Therefore, patients from other centers were included only if eligible for radiological evaluation (ie, availability of the required CT scans, adequate intervals between them, and the presence of the target lesions). In cases of progression, if the patient was clinically stable, PD-1/PD-L1 inhibitors could be continued, with a subsequent evaluation at least 4 weeks later, according to immunotherapy response criteria recommendations. 12 Pseudoprogression was defined as initial progression, followed by complete response or partial response or stable disease lasting more than 6 months. 13 
Tumor Growth Rate
The TGR was calculated according to the definition by Ferté et al 14 and was computed from the sum of the largest diameters of the target lesions as per RECIST version 1.1 (eMethods in the Supplement). The TGR results were reported as a percentage increase in tumor volume per month. New lesions and nonmeasurable disease were excluded from the RECIST version 1.1 sum, and the TGR was only quantified for the target lesions. 14 The TGR was measured before and after PD-1/PD-L1 inhibitors (or chemotherapy in the control cohort). The difference (ΔTGR is the TGR on treatment minus the TGR before treatment) was used to assess the association of treatment with tumor growth. Delta TGR exceeding 0% means that treatment may accelerate tumor growth.
Hyperprogressive disease was defined as RECIST version 1.1 progressive disease on the first CT scan during treatment
Key Points
Question Do programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors accelerate tumor growth, a phenomenon defined as hyperprogressive disease?
Findings In this multicenter cohort study including 406 patients with advanced non-small cell lung cancer (NSCLC) treated with PD-1/PD-L1 inhibitors, hyperprogressive disease was observed in 13.8% (n = 56) of the population. Patients experiencing hyperprogression had significantly worse overall survival (3.4 months) compared with patients with progression not classified as hyperprogressive disease (6.2 months).
Meaning Hyperprogressive disease is a novel pattern of progression in patients receiving treatment with PD-1/PD-L1 inhibitors for NSCLC, of which patients and clinicians should be aware to properly select the best treatment and carefully monitor disease evolution.
and ΔTGR exceeding 50%, corresponding to an absolute increase in the TGR exceeding 50% per month. A graphical representation of the hypothetical tumor volume variation and the HPD definition for the immunotherapy cohort is shown in Figure 1 .
Statistical Analysis
Associations between HPD and categorical or continuous variables were evaluated using the Fisher exact test and the t test, respectively. Because the diagnosis of HPD depends on the timing of the radiological assessment and could induce a lead-time bias, 15 a landmark analysis was performed to assess the association of HPD with overall survival (OS) using a time point at 6 weeks after PD-1/PD-L1 inhibitor or chemotherapy initiation. Patients alive at this time point and with progression on their first CT scan during PD-1/PD-L1 inhibitor therapy or chemotherapy were considered hyperprogressors or not hyperprogressors according to the diagnosis of HPD within the first 6 weeks of treatment. Overall survival curves were estimated with the Kaplan-Meier method and compared by the log-rank test. The hazard ratio (HR) was estimated using the univariate Cox proportional hazards regression model. All P values were 2 sided, and values less than .05 were considered statistically significant. Statistical analyses were performed using a software program (SAS for Windows, version 9.4; SAS Institute Inc).
Results
Immunotherapy Cohort
Overall, 406 patients (63.8% male) were included in the TGR analysis. The reasons for exclusion were evaluated in a singlecenter cohort (at Gustave Roussy, Villejuif, France) (n = 249) and included the following: unavailability of CT scans before baseline, at baseline, or during PD-1/PD-L1 inhibitor therapy; inadequate intervals between CT scans; or the absence of measurable disease. Of 249 patients, 76 (30.5%) were not evaluable for the TGR analysis, among whom 13.3% (33 of 249) experienced clinical progression and/or death before the first tumor evaluation during PD-1/PD-L1 inhibitor therapy (eFigure 1 in the Supplement).
The main characteristics of the 406 patients in the immunotherapy multicenter cohort are listed in the Table. The median follow-up was 12.1 months (95% CI, 10.1-13.8 months), the objective response rate was 18.9% (77 of 406), and 41.9% (170 of 406) of patients had progressive disease as the best response to immunotherapy (eTable 1 in the Supplement). The median progression-free survival (PFS) and OS were 2.1 months (95% CI, 1.8-3.1 months) and 13.4 months (95% CI, 10.2-17.0 months), respectively.
Before immunotherapy, 75 of 406 patients (18.5%) had a TGR of 0 or less (eTable 2 in the Supplement), but all were classified as having progressive disease because of the appearance of new lesions or progression in the nontarget lesions. During immunotherapy, the TGR was stable or decreased (ΔTGR ≤0) in 266 patients (65.5%) and increased (ΔTGR >0) in 140 patients (34.5%). Among them, 62 patients (15.3% of the overall population) were initially classified as having HPD ( Figure 2A and Figure 3) .
Overall, 19 patients (4.7%) had progressive disease, followed by complete response and/or partial response or stable disease longer than 6 months, and were thus classified as pseudoprogressors (eTable 1 in the Supplement). Six pseudoprogressors were initially classified as having HPD on the first CT scan. Excluding these 6 patients from the 62 patients with HPD, the definitive rate of HPD was 13.8% (56 patients). Hyperprogressive disease was significantly associated with more than 2 metastatic sites before PD-1/PD-L1 inhibitors compared with non-HPD (62.5% [35 of 56] vs 42.6% [149 of 350]; P = .006) (Table) . No significant differences were observed according to the baseline tumor burden, the number of previous lines of therapy (eFigure 2 in the Supplement), or age (Table) .
In the landmark survival analysis, patients experiencing HPD within the first 6 weeks of beginning PD-1/PD-L1 inhibitor therapy (n = 23) had significantly lower OS compared with Figure 4A) . As a sensitivity analysis, 2 other landmark time points were tested. With a time point at 4 weeks, the difference in OS remained significant. However, when choosing a time point of 8 weeks, the difference in OS did not reach statistical significance.
Chemotherapy Cohort
Overall, 59 patients were included in the TGR analysis. The reasons for exclusion were evaluated in a single-center cohort (at Gustave Roussy) (n = 77) (eFigure 3 in the Supplement). The main characteristics of the 59 patients are listed in eTable 3 in the Supplement. The median follow-up was 26.3 months (95% CI, 22.6-35.5 months), the objective response rate was 10.2% (6 of 59), and 30.5% (18 of 59) of patients had progressive disease as the best response (eTable 1i nt h eSupplement). The median PFS and OS were 3.9 months (95% CI, 3.1-4.8 months) and 8.6 months (95% CI, 6.2-13.4 months), respectively. No pseudoprogression was observed.
The TGR analysis is summarized in eTable 2 in the Supplement. Delta TGR was greater than 0 in 12 patients; among them, 3 patients were classified as having HPD ( Figure 2B) . A landmark analysis at 6 weeks showed a median OS of 4.5 months (95% CI, 2.5-6.5 months) in patients diagnosed as having HPD (n = 3) and 3.9 months (95% CI, 2.7-6.9 months) in other patients with progressive disease (ie, non-HPD patients with progressive disease at the first evaluation [n = 18]) (P = .60) ( Figure 4B ). 
Research Original Investigation
Hyperprogressive Disease in Patients With Advanced NSCLC Treated With PD-1/PD-L1 Inhibitors 5 the progression rate was 44% with nivolumab and 29% with docetaxel, with an excess of 14 deaths during the first 3 months in the nivolumab arm. 16 As a result, OS curves crossed at 6 months, with an initial survival benefit in favor of docetaxel. In addition, a recent retrospective study 17 reported that approximately 15% of early deaths were due to disease progression during the first 3 months of nivolumab treatment in patients with advanced NSCLC. The European Medicines Agency recently included an alert in the summary of product information for nivolumab regarding treatment of patients with NSCLC with poor prognostic features or aggressive disease. 18 In our study, the absence of a significant survival difference using a landmark analysis at 8 weeks is likely because of the small number of patients with HPD alive at that time point and eligible for the landmark analysis. This finding further suggests that HPD is a rapid phenomenon, which leads to early death mostly in the first 2 months of treatment.
There is no consensus on the optimal definition of HPD. Champiat et al 9 defined HPD as progressive disease at the first evaluation in addition to an increase of at least 2-fold in the TGR during PD-1/PD-L1 inhibitor therapy compared with the TGR before PD-1/PD-L1 inhibitors. Saâda-Bouzid et al 10 described HPD as an increase of at least 2-fold in tumor growth kinetics after PD-1/PD-L1 inhibitor initiation, which measured the variation of the sum of the largest diameters of the target lesions per unit of time during immunotherapy compared with tumor growth kinetic before PD-1/PD-L1 inhibitors. We used a stringent definition of HPD that requires a high-volume increase per month to classify a patient as a hyperprogressor. For example, a tumor with a 20% volume increase per month before immunotherapy had to have a 70% increase per month during immunotherapy to be labeled as HPD. Despite the differences in methods, the present analysis and the 2 previous studies 9, 10 highlight the importance of quantifying tumor growth speed to discriminate between progression due to natural history of the disease (the tumor growth speed is already high before the start of the new treatment) and progression due to the potential intrinsic association of the experimental treatment (the tumor growth speed is lower before the start of the new treatment). Unfortunately, the TGR assessment cannot be validated in published randomized studies because the radiological evaluations before the baseline CT scan data were not captured. In our immunotherapy cohort, HPD was significantly associated with a high number of metastatic sites before PD-1/ PD-L1 inhibitors, whereas no association with the baseline tumor burden was found. However, the target lesions defined by RECIST version 1.1 do not always perfectly reflect the whole tumor burden, especially in patients with nonmeasurable dis- comparison of these numbers should be interpreted with caution in the absence of a common definition of pseudoprogression across the studies. 33 We identified HPD in only 3 of 59 patients (5.1%) treated with single-agent chemotherapy, and no pseudoprogression was described, suggesting that these patterns are new and specific to PD-1/PD-L1 inhibitors. To our knowledge, the present study is the largest analysis exploring HPD to date and is the first conducted in a dedicated NSCLC population. In addition, we believe that this is the only study to include a control cohort of chemotherapytreated patients with NSCLC and is thus able to assess the negative association with survivial of HPD compared with conventional disease progression during PD-1/PD-L1 inhibitor therapy. Although in some immunotherapy trials 5,6,8 the first CT scan was performed at week 9, the fact that HPD drives toward early death (mainly in the first 6 weeks of treatment) prompts discussion over an anticipated first radiological evaluation during PD-1/PD-L1 inhibitor therapy to properly identify hyperprogressors. Ultimately, because of the poor OS associated with HPD, an early switch to salvage chemotherapy in these patients should be considered.
Limitations
Our study has some limitations, mainly related to its retrospective nature. ) and PD-1/PD-L1 inhibitor-PD-1/PD-L1 inhibitor (CheckMate 227 study 4 ) combinations compared with platinum doublets has been reported. In high-TMB patients with NSCLC, the PFS curves of nivolumab plus ipilimumab and platinumbased chemotherapy treatments cross between 3 and 6 months; in patients receiving platinum-based chemotherapy in combination with pembrolizumab or placebo, an early separation of both PFS and OS curves has been observed. ies with prospective assessment of tumor and blood samples from patients with HPD both before treatment and on treatment help clarify the mechanisms behind this phenomenon and its causal relation to treatment.
Conclusions
We identified HPD in 13.8% (56 of 406) of patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors and in only 5.1% (3 of 59) of patients with advanced NSCLC treated with single-agent chemotherapy. In this study, HPD was associated with a high number of metastatic sites at baseline and poor survival (3.4 months), suggesting a detrimental association of immunotherapy in a subset of patients with NSCLC. Additional studies are needed to characterize the molecular basis of HPD.
eMethods. Supplemental Methods
Computation of tumor growth rate (TGR) and timing of TGR assessment
Assuming tumor growth follows an exponential law, Vt, tumor volume at time t (expressed in months in the tumor evaluation) is equal to Vt = V0 exp (TG.t), where V0 is volume at baseline, and TG is the growth rate. We approximated the tumor volume (V) by V=4 R3/3, where R, the radius of the sphere, is equal to D/2. Consequently, TG is equal to TG=3 log(Dt/D0)/(t1-t0), where log represents natural logarithms and t1-t0 is the time between evaluations in months. TGR results were reported as a percent increase in tumor volume per month using the following transformation: TGR=100 [exp(TG)−1], where exp(TG) represents the exponential of TG 1 . The algorithm for TGR calculation is publicly available online (https://github.com/chferte/TumorGrowthRate/blob/master/TGR_calculator.R). Tumor volume was evaluated at three timepoints: before treatment with IO or chemotherapy [(n-1) CT scan], at baseline [baseline (n) CT scan], and once during treatment [(n+1) CT scan]. TGR was then calculated before [(n) CT scan vs (n-1) CT scan] and during [(n+1) CT scan vs (n) CT scan] for both the PD-1/PD-L1 inhibitor cohort and singleagent chemotherapy cohort.
